Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
Publications
Publications
  • September–October 2020
  • Article
  • NEJM Catalyst Innovations in Care Delivery

The Past, Present, and (Near) Future of Gene Therapy and Gene Editing

By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
  • Format:Electronic
ShareBar

Abstract

Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused therapies in the years ahead. The number of clinical trials and venture capital deals increased substantially from 2006–2017. We observed particularly notable growth in both industry-sponsored trials and trials involving specialty fields of drug development, including oncology, neurology, hematology, ophthalmology, and neurology. As the number of gene-therapy and gene-editing technologies continues to grow, we expect that such therapies will have a significant and heterogeneous impact on health-care delivery, including a shifting of resources from chronic disease management to more intense acute episodic care, an increase in the complexity of required intellectual property and manufacturing know-how, and the potential expansion of biopharmaceutical companies into service-based business models.

Keywords

Gene Therapy; Gene Editing; Impact; Health Care And Treatment; Technological Innovation; Health Testing And Trials; Venture Capital; Change

Citation

Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
  • Find it at Harvard
  • Read Now

About The Authors

Amitabh Chandra

Technology and Operations Management
→More Publications

Ariel D. Stern

Technology and Operations Management
→More Publications

More from the Authors

    • January 2021
    • Faculty Research

    Value-Based Insurance Design at Onex

    By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal
    • January–February 2021
    • American Journal of Therapeutics

    Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses

    By: Rachel E. Weitzman, Ariel Dora Stern and Daniel B. Kramer
    • Harvard Business Review (website)

    Want to See the Future of Digital Health Tools? Look to Germany

    By: Ariel Dora Stern, Henrik Matthies, Julia Hagen, Jan B. Brönneke and Jörg F. Debatin
More from the Authors
  • Value-Based Insurance Design at Onex By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal
  • Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses By: Rachel E. Weitzman, Ariel Dora Stern and Daniel B. Kramer
  • Want to See the Future of Digital Health Tools? Look to Germany By: Ariel Dora Stern, Henrik Matthies, Julia Hagen, Jan B. Brönneke and Jörg F. Debatin
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Digital Accessibility
Copyright © President & Fellows of Harvard College